Pharmacokinetics and tolerability of lamotrigine and olanzapine coadministered to healthy subjects

British Journal of Clinical Pharmacology

Volumn 61, Issue 4, 2006, Pages 420-426

  Sidhu, Jagdev ^a   Job, Sarah ^a   Bullman, Jonathan ^a   Francis, Emma ^a   Abbott, Richard ^b   Ascher, John ^b   Theis, Jochen G W ^c  

^a GLAXOSMITHKLINE   (United Kingdom)

^b University of Cambridge ^*

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Lamotrigine; Olanzapine; Pharmacokinetics; Tolerability

Indexed keywords

AMINOTRANSFERASE; CLOZAPINE; LAMOTRIGINE; OLANZAPINE; PLACEBO;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DETERMINATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FATIGUE; FREQUENCY ANALYSIS; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; TITRIMETRY;

EID: 33645028734     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02598.x     Document Type: Article

References (15)

1. Nemeroff CB An ever-increasing pharmacopoeia for the management of patients with bipolar disorder J Clin Psychiat 2000 61 Suppl 13 19 25
2. Freeman MP Stoll AL Mood stabilizer combinations: a review of safety and efficacy Am J Psychiat 1998 155 12 21
3. Bowden CL Calabrese JR Sachs G Yatham LN Behnke K Mehtonen OP Montgomery P Ascher J Paska W Earl N DeVeaugh-Geiss J A placebo-controlled, 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder Arch General Psychiat 2003 60 392 400
4. Calabrese J Bowden C Sachs G Yatham LN Behnke K Mehtonen OP Montgomery P Ascher J Paska W Earl N DeVeaugh-Geiss J A placebo-controlled, 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder J Clin Psychiat 2003 64 1013 24
5. Baldessarini RJ Hennen J Wilson M Calabrese J Chengappa R Keck PE Jr McElroy SL Sachs G Vieta E Welge JA Yatham LN Zarate CA Jr Baker RW Tohen M Olanzapine versus placebo in acute mania: treatment responses in subgroups J Clin Psychopharm 2003 23 370 6
6. Tohen M Goldberg JF Gonzalez-Pinto AAM Azorin JM Vieta E Hardy-Bayle MC Lawson WB Emsley RA Zhang F Baker RW Risser RC Namjoshi MA Evans AR Breier A A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania Arch General Psychiat 2003 60 1218 26
7. Goodwin GM Bowden CL Calabrese JR Grunze H Kasper S White R Greene P Leadbetter R A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder J Clin Psychiat 2004 65 432 41
8. Ramsey RE Pellock JM Garnett WR Sanchez RM Valakas AM Wargin WA Lai AA Hubbell J Chern WH Allsup T Pharmacokinetic and safety of lamotrigine (Lamictal) in patients with epilepsy Epilepsy Res 1991 10 191 200
9. Magdalou J Herber R Bidault R Siest G In vitro N-glucuronidation of a novel antiepileptic drug, lamotrigine, by human liver microsomes J Pharmacol Exp Ther 1992 260 1166 73
10. Kassahun K Mattiuz EL Nyhart E Obermeyer B Gillespie T Murphy A Goodwin RM Tupper D Callaghan JT Lemberger L Disposition and biotransformation of the antipsychotic agent olanzapine in humans Drug Metab Dispos 1997 25 81 93
11. Ring BJ Catlow J Lindsay TJ Gillespie T Roskos LK Cerimele BJ Swanson SP Hamman MA Wrighton SA Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine J Pharmacol Exp Ther 1996 276 658 66
12. Keck PE McElroy SL Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications J Clin Psychiat 2002 63 Suppl 4 3 11
13. Linnet K Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes Hum Psychopharmacol 2002 17 233 8
14. Chinchilli VM The assessment of individual and population bioequivalence J Biopharmaceut Stat 1996 6 1 14
15. Beasley CM Jr. Tollefson GD Tran PV Safety of olanzapine J Clin Psychiat 1997 58 Suppl 10 13 17